Ovarian cancer is one of those. Ovarian cancer starts in the ovaries, which are two small glands located on either side of ...

Researchers developed a wearable pad that detects inflammation and cancer biomarkers in menstrual blood using smartphone ...

To provide updated guidance regarding neoadjuvant chemotherapy (NACT) and primary cytoreductive surgery (PCS) among patients with stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal ...

Can you discuss the implications of these data? Ovarian cancer is a difficult cancer to treat, in the fact that there is no good screening tool. There have been many studies looking at laboratory ...

kDepartment of Gynecology and Obstetrics, Hospital Anregiomed Ansbach, Ansbach, Germany lDepartment of Obstetrics and Gynecology, University Hospital Aachen, Aachen, Germany mViDia Christliche ...

was previously evaluated as a first-line treatment for patients with BRCA non-mutated advanced epithelial ovarian cancer. Despite proving improvements in progression-free survival, the Keytruda-Ly ...

In the published article, there was an error in the Funding statement. “The author(s) declare financial support was received for the research, authorship, and/or ...

Eligible study participants were adult females for whom there was a high clinical suspicion or diagnosis of epithelial ovarian cancer. Planned surgeries included primary surgical cytoreduction, ...

MONDAY, May 12, 2025 (HealthDay News) — The addition of bevacizumab to first-line (1L) chemotherapy offers real-world benefit to patients with epithelial ovarian cancer with high-risk prognostic ...

In its 15th year, Verastem Oncology has gained its first FDA approval, winning an accelerated nod for the combination treatment of avutometinib and defactinib for a rare form of ovarian cancer.

New research led by Irish scientists has uncovered how lipid-rich fluid in the abdomen, known as ascites, plays a central role in weakening the body's immune response in advanced ovarian cancer.